<DOC>
	<DOCNO>NCT00168987</DOCNO>
	<brief_summary>Malnutrition frequent symptom various malignant disease frequently observe patient gastrointestinal tumor . Eicosapentanoic acid ( EPA ) introduce specific anticatabolic act substrate cancer patient . Only randomized trial available investigated effect EPA form EPA-enriched , protein- energy-dense oral nutritional supplement mostly patient pancreatic carcinoma . Therefore , effect EPA-rich oral nutritional supplement two month functional state quality life patient gastroenterological tumor weight loss investigate randomized prospective trial .</brief_summary>
	<brief_title>Influence Oral Nutritional Supplement Rich Omega-3 Fatty Acids Functional State Quality Life Malnourished Patients With Gastroenterological Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Malnutrition</mesh_term>
	<criteria>malignant disease : colorectal neoplasm , hepatocellular carcinoma , cholangiocarcinoma palliative treatment malignant disease : UICC stage &gt; 1 impaired nutritional state : weight loss &gt; 5 % body weight precede 6 month subjective global assessment grade B ( moderately malnourish ) grade C ( severely malnourish ) inform write consent age &lt; 18 year pregnancy exclusive enteral parenteral nutrition take eicosapentanoic acid form fish oil capsule contraindication oral nutrition ( i.e . ileus , uncontrollable vomit ) terminal stage disease life expectancy &lt; 3 month miss withdrawn consent simultaneous participation another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>oral nutritional supplement</keyword>
	<keyword>eicosapentanoic acid</keyword>
	<keyword>gastroenterological tumor</keyword>
	<keyword>muscle function</keyword>
	<keyword>quality life</keyword>
	<keyword>body composition</keyword>
</DOC>